恒瑞医药(600276) - 2024 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2024 reached CNY 5,997,533,912.14, representing a year-on-year increase of 9.20%[4] - The net profit attributable to shareholders was CNY 1,368,929,247.85, reflecting a growth of 10.48% compared to the same period last year[4] - The basic earnings per share for the quarter were CNY 0.21, an increase of 10.53% year-on-year[4] - Total operating revenue for Q1 2024 reached 1,636,008,814.62 CNY, an increase of 21.7% compared to 1,344,430,121.81 CNY in Q1 2023[18] - Net profit for Q1 2024 was 1,367,488,687.72 CNY, up 10.9% from 1,233,392,458.39 CNY in the same period last year[18] - Total comprehensive income for Q1 2024 was 1,361,563,296.04 CNY, compared to 1,213,706,432.37 CNY in Q1 2023, showing a growth of 12.2%[18] Cash Flow and Operating Activities - The net cash flow from operating activities surged by 486.35%, amounting to CNY 1,254,598,909.00, driven by increased revenue and faster customer payments[4][7] - Cash flow from operating activities generated a net amount of 1,254,598,909.00 CNY, significantly higher than 213,969,280.70 CNY in Q1 2023[20] - The company experienced a significant increase in cash inflows from operating activities, totaling 6,136,051,366.98 CNY in Q1 2024, compared to 4,016,914,028.75 CNY in Q1 2023[20] Assets and Liabilities - The total assets at the end of Q1 2024 were CNY 46,340,001,350.84, up 5.84% from the end of the previous year[5] - The total current assets as of March 31, 2024, amounted to CNY 33,712,251,970.65, up from CNY 31,287,471,171.21 at the end of 2023, reflecting a growth of 7.8%[13] - The total liabilities as of March 31, 2024, were CNY 3,900,646,048.76, compared to CNY 2,751,420,194.43 at the end of 2023, indicating a significant increase of 41.8%[15] - The company's retained earnings reached CNY 30,171,699,562.75 as of March 31, 2024, compared to CNY 28,802,770,314.90 at the end of 2023, an increase of 4.8%[15] Shareholder Information - The equity attributable to shareholders increased to CNY 41,873,504,779.57, marking a 3.48% rise compared to the previous year[5] - The top ten shareholders held a total of 2,882,000,000 shares, representing 45.04% of the total shares outstanding[9] Research and Development - Research and development expenses for Q1 2024 were 1,220,126,943.52 CNY, up from 1,148,839,463.56 CNY in Q1 2023, indicating a focus on innovation[18] Other Financial Metrics - The weighted average return on net assets was 3.33%, an increase of 0.1 percentage points compared to the previous year[4] - Non-recurring gains and losses totaled CNY -71,551,034.89 for the quarter, primarily due to other operating income and expenses[6] - The company reported a decrease in financial expenses, with a net financial cost of -148,635,537.78 CNY in Q1 2024, compared to -68,336,855.94 CNY in Q1 2023[18]